{"id":"NCT01219855","sponsor":"OPKO Health, Inc.","briefTitle":"Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)","officialTitle":"A Randomized, Double Blind, Placebo-Controlled, Repeat Dose, Safety, Efficacy and Pharmacokinetic/Pharmacodynamic Study of CTAP101 Capsules in Subjects With Chronic Kidney Disease, Vitamin D Insufficiency and Secondary Hyperparathyroidism","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2010-10","primaryCompletion":"2011-11","completion":"2011-11","firstPosted":"2010-10-13","resultsPosted":"2016-08-25","lastUpdate":"2016-08-25"},"enrollment":78,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Kidney Disease","Secondary Hyperparathyroidism","Vitamin D Insufficiency"],"interventions":[{"type":"DRUG","name":"Cohort 1 CTAP101 Capsules- 60µg","otherNames":[]},{"type":"DRUG","name":"Cohort 1 CTAP101 Capsules - 90µg","otherNames":[]},{"type":"DRUG","name":"Cohort 1 Matching Sugar Capsule","otherNames":[]},{"type":"DRUG","name":"Cohort 2 CTAP101 Capsules - 30µg","otherNames":[]},{"type":"DRUG","name":"Cohort 2 Matching Sugar Capsule","otherNames":[]}],"arms":[{"label":"Cohort 1: CTAP101 Capsules 60µg","type":"EXPERIMENTAL"},{"label":"Cohort 1: CTAP101 Capsules 90µg","type":"EXPERIMENTAL"},{"label":"Cohort 1: Sugar Capsule","type":"PLACEBO_COMPARATOR"},{"label":"Cohort 2: CTAP101 Capsules 30µg","type":"EXPERIMENTAL"},{"label":"Cohort 2: Sugar Capsule","type":"PLACEBO_COMPARATOR"}],"summary":"This study will investigate how the levels of a repeat dose of CTAP101 changes in the body over time (pharmacokinetics, PK) and how CTAP101 affects other mineral and hormonal balances (pharmacodynamics, PD) in patients with chronic kidney disease (CKD, vitamin D insufficiency and secondary hyperparathyroidism (SHPT).","primaryOutcome":{"measure":"Proportion (%) of Subjects With Serum 25-hydroxyvitamin D ≥30 ng/mL (PP).","timeFrame":"6 weeks","effectByArm":[{"arm":"Cohort 1: CTAP101 Capsules 60µg","deltaMin":100,"sd":null},{"arm":"Cohort 1: CTAP101 Capsules 90µg","deltaMin":100,"sd":null},{"arm":"Cohort 1: Sugar Capsule","deltaMin":0,"sd":null},{"arm":"Cohort 2: CTAP101 Capsules 30µg","deltaMin":91.7,"sd":null},{"arm":"Cohort 2: Sugar Capsule","deltaMin":7.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001 vs OG003 vs OG004","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":31},"commonTop":["Oedema peripheral","Contusion","Headache","Gout","Abdominal discomfort"]}}